Intelligent Medicine Acquisition Corp.

General Information
We intend to focus our search on life science companies that are using artificial intelligence (“AI”), machine learning (“ML”) and big data to create and power a new model of drug discovery through research and development that is far faster, less expensive and more predictable than the decades-old system of drug development we still follow today.
With a broadening set of applications for biotechnology that includes research tools and infrastructure, diagnostics, therapeutics, data, and industrial outputs, we believe the life sciences sector offers compelling opportunities for investors who possess a broad overview and understand the trends and themes.


Our CEO is Gregory Simon, the former executive director of the White House Cancer Moonshot Task Force.

(Note: Intelligent Medicine Acquisition Corp. upsized its SPAC IPO at pricing on Nov. 4, 2021, to 18 million units, up from 15 million in the prospectus, at $10 each to raise $180 million.)

Employees: 0
Founded: 2021
Contact Information
Address 9001 Burdette Rd. Bethesda, MD 20817
Phone Number (202) 905-5834
Web Address
View Prospectus: Intelligent Medicine Acquisition Corp.
Financial Information
Market Cap $190.5mil
Revenues $0 mil (last 12 months)
Net Income $0 mil (last 12 months)
IPO Profile
Symbol IQMDU
Exchange NASDAQ
Shares (millions): 18.0
Price range $10.00 - $10.00
Est. $ Volume $180.0 mil
Manager / Joint Managers Cantor Fitzgerald
CO-Managers -
Expected To Trade: 11/5/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change